{"created":"2021-03-01T06:35:02.937180+00:00","id":27083,"links":{},"metadata":{"_buckets":{"deposit":"f64153cd-7c84-4f60-8763-8c64333ce0f3"},"_deposit":{"id":"27083","owners":[],"pid":{"revision_id":0,"type":"depid","value":"27083"},"status":"published"},"_oai":{"id":"oai:nagoya.repo.nii.ac.jp:00027083","sets":["499:500:501"]},"author_link":["88794","88795","88796","88797","88798","88799","88800","88801","88802","88803"],"item_10_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-11","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"11","bibliographicPageEnd":"1030","bibliographicPageStart":"1023","bibliographicVolumeNumber":"23","bibliographic_titles":[{"bibliographic_title":"Nephrology","bibliographic_titleLang":"en"}]}]},"item_10_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Aim: We aimed to evaluate the anti‐albuminuric effects of topiroxostat in Japanese hyperuricaemic patients with diabetic nephropathy. Methods: In this 24‐week, multicentre, open‐label, randomized (1 : 1) trial, we assigned hyperuricaemic patients with diabetic nephropathy (estimated glomerular filtration rate ≥ 20 mL/min per 1.73m2) and overt proteinuria (0.3 ≤ urine protein to creatinine ratio (UPCR) <3.5 g/g Cr) to either high dose (160 mg daily) or low dose (40 mg daily) topiroxostat. The primary endpoint was the change in albuminuria indicated by urine albumin‐to‐creatinine ratio (UACR) from the baseline at the final time point. Results: A total of 80 patients underwent randomization. The changes in UACR after 24 weeks of treatment (or at the final time point if patients failed to reach 24 weeks) relative to the baseline were −122 mg/gCr (95% CI: −5.1 to −240.1, P = 0.041) in patients treated with high dose, while treatment with low dose topiroxostat could not show significant reduction (P = 0.067). In the linear mixed model including baseline albuminuria, eGFR, age, and sex as covariates, the decreases in UACR were still significant from baseline to 12 weeks by 228.7 ± 83.2 mg/gCr (P = 0.0075) in the high dose group. The adverse‐event profile during this study was not different between the groups. Conclusion: Topiroxostat 160 mg daily reduced albuminuria in patients with diabetic nephropathy. (Funded by Sanwa Kagaku Kenkyusho; Trial registration, UMIN000015403). ","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"ファイル公開：2019-11-01","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Wiley","subitem_publisher_language":"en"}]},"item_10_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1111/nep.13177","subitem_relation_type_select":"DOI"}}]},"item_10_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"This is the peer reviewed version of the following article: [Mizukoshi, T. , Kato, S. , Ando, M. , Sobajima, H. , Ohashi, N. , Naruse, T. , Saka, Y. , Shimizu, H. , Nagata, T. and Maruyama, S. (2018), Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial. Nephrology, 23: 1023-1030. doi:10.1111/nep.13177], which has been published in final form at [https://doi.org/10.1111/nep.13177]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.","subitem_rights_language":"en"}]},"item_10_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"author"}]},"item_10_source_id_61":{"attribute_name":"ISSN（print）","attribute_value_mlt":[{"subitem_source_identifier":"1320-5358","subitem_source_identifier_type":"PISSN"}]},"item_1615787544753":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Mizukoshi, Toshihiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"88794","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kato, Sawako","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"88795","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ando, Masahiko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"88796","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sobajima, Hiroshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"88797","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ohashi, Norimi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"88798","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Naruse, Tomohiko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"88799","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saka, Yosuke","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"88800","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shimizu, Hideaki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"88801","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nagata, Takanobu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"88802","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Maruyama, Shoichi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"88803","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-11-01"}],"displaytype":"detail","filename":"1_repositoryETUDE_Nephrology.pdf","filesize":[{"value":"1.7 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"1_repositoryETUDE_Nephrology","objectType":"fulltext","url":"https://nagoya.repo.nii.ac.jp/record/27083/files/1_repositoryETUDE_Nephrology.pdf"},"version_id":"fee2d56d-0b17-49a0-aef7-de207c641be4"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"albuminuria","subitem_subject_scheme":"Other"},{"subitem_subject":"diabetic nephropathy","subitem_subject_scheme":"Other"},{"subitem_subject":"randomized study","subitem_subject_scheme":"Other"},{"subitem_subject":"topiroxostat","subitem_subject_scheme":"Other"},{"subitem_subject":"xanthine oxidoreductase inhibitor","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial","subitem_title_language":"en"}]},"item_type_id":"10","owner":"1","path":["501"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2019-02-13"},"publish_date":"2019-02-13","publish_status":"0","recid":"27083","relation_version_is_last":true,"title":["Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-01-16T04:43:44.504781+00:00"}